Enanta Pharmaceuticals (ENTA) Other Accumulated Expenses (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Other Accumulated Expenses data on file, last reported at $1.2 million in Q1 2026.

• Quarterly Other Accumulated Expenses fell 23.36% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 23.36% YoY) and the FY2025 annual result came in at $1.8 million, down 94.78% from the prior year.
• Other Accumulated Expenses declined to $1.2 million in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $36.7 million in Q2 2023 to a low of $867000.0 in Q1 2023.
• A 5-year average of $13.1 million and a median of $2.1 million in 2025 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses jumped 3783.62% — and 2025, when it plunged 95.33%.
• Tracing ENTA's Other Accumulated Expenses over 5 years: stood at $6.9 million in 2022, then slumped by 63.76% to $2.5 million in 2023, then slumped by 41.7% to $1.4 million in 2024, then soared by 41.66% to $2.1 million in 2025, then plunged by 41.38% to $1.2 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.2 million (Q1 2026), $2.1 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.